Hi Guys,
I am so pleased we seem to be progressing in the right direction. The fact we are also presenting at the American Academy of Neurology (AAN) is a massive step forward. To have 3 Representatives approved to be presenting at that conference certainly speaks volumes.
Now, news that we have been given full approval by the DMC to continue with our trial all the way through 2024 is fantastic! This just proves that ATH434 is safe and showing no adverse effects to those participating in the trial. Its another big TICK!!
I am very excited to see the results from the bioMUSE study start to roll through from March onwards. Definitely big things on the horizon for Alterity this year. Good thing March is around the corner!
GLTAH
Stockman...
Ann: Phase 2 DMC Recommends Continuing Clinical Trial as Planned, page-9
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $3.446K | 695K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 80636710 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 19070116 | 14 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 537000 | ||
| Last updated 14.20pm 13/06/2024 ? | |||||
| ATH (ASX) Chart |